Devazepid

Devazepid
IUPAC ime
	N-(1-methyl- 2-oxo- 5-phenyl- 3H-1,4-benzodiazepin-3-yl)- 1H-indole -2-carboxamide
Identifikatori
CAS broj	103420-77-5
ATC kod	none
PubChem	CID 59751
IUPHAR/BPS	878
KEGG	D02693
ChEMBL	CHEMBL153326
Hemijski podaci
Formula	C25H20N4O2
Molarna masa	408.452 g/mol
	SMILES CN1C2=CC=CC=C2C(=NC(C1=O)NC(=O)C3=CC4=CC=CC=C4N3)C5=CC=CC=C5; ;

Devazepid (L-364,718, MK-329) je lek koji je strukturni derivat benzodiazepinske familije, ali se po dejstvu veoma razlikuje od većine benzodiazepina. On nema afiniteta za GABA_A receptore i umesto toga deluje kao holecistokininski antagonist koji je selektivan za CCK_A tip receptora.^[1] On povećava apetit i ubrzava želudačano pražnjenje,^[2]^[3] i smatra se da on potencijalno može da služi kao lek za niz gastrointestinalnih problema, među kojima su dispepsija, gastropareza i gastroezofagealna refluksna bolest.^[4] On je u širokoj upotrebi u naučnim istraživanjima CCK_A receptora.^[5]^[6]^[7]

Reference[уреди | уреди извор]

^ Hill DR, Woodruff GN. Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260. Brain Research. 1990 Sep 3;526(2):276-83. PMID 2257485
^ Cooper SJ, Dourish CT. Multiple cholecystokinin (CCK) receptors and CCK-monoamine interactions are instrumental in the control of feeding. Physiology and Behaviour. 1990 Dec;48(6):849-57. PMID 1982361
^ Cooper SJ, Dourish CT, Clifton PG. CCK antagonists and CCK-monoamine interactions in the control of satiety. American Journal of Clinical Nutrition. 1992 Jan;55(1 Suppl):291S-295S. PMID 1728842
^ Scarpignato C, Varga G, Corradi C. Effect of CCK and its antagonists on gastric emptying. Journal of Physiology Paris. 1993;87(5):291-300. PMID 8298606
^ Weller A. The ontogeny of postingestive inhibitory stimuli: examining the role of CCK. Developmental Psychobiology. 2006 Jul;48(5):368-79. PMID 16770766
^ Savastano DM, Covasa M. Intestinal nutrients elicit satiation through concomitant activation of CCK(1) and 5-HT(3) receptors. Physiology and Behaviour. 2007 Oct 22;92(3):434-42. PMID 17531277
^ Evans, B. E.; Rittle, K. E.; DiPardo, R. M.; Freidinger, R. M.; Whitter,W. L.; People,W. T.; Lendell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirschfield, J. (1988). J. Med. Chem. 31: 2235 http://dx.doi.org/10.1021/jm00120a002. Недостаје или је празан параметар |title= (помоћ)

Spoljašnje veze[уреди | уреди извор]

[1] Hill DR, Woodruff GN. Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260. Brain Research. 1990 Sep 3;526(2):276-83. PMID 2257485

[2] Cooper SJ, Dourish CT. Multiple cholecystokinin (CCK) receptors and CCK-monoamine interactions are instrumental in the control of feeding. Physiology and Behaviour. 1990 Dec;48(6):849-57. PMID 1982361

[3] Cooper SJ, Dourish CT, Clifton PG. CCK antagonists and CCK-monoamine interactions in the control of satiety. American Journal of Clinical Nutrition. 1992 Jan;55(1 Suppl):291S-295S. PMID 1728842

[4] Scarpignato C, Varga G, Corradi C. Effect of CCK and its antagonists on gastric emptying. Journal of Physiology Paris. 1993;87(5):291-300. PMID 8298606

[5] Weller A. The ontogeny of postingestive inhibitory stimuli: examining the role of CCK. Developmental Psychobiology. 2006 Jul;48(5):368-79. PMID 16770766

[6] Savastano DM, Covasa M. Intestinal nutrients elicit satiation through concomitant activation of CCK(1) and 5-HT(3) receptors. Physiology and Behaviour. 2007 Oct 22;92(3):434-42. PMID 17531277

[7] Evans, B. E.; Rittle, K. E.; DiPardo, R. M.; Freidinger, R. M.; Whitter,W. L.; People,W. T.; Lendell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirschfield, J. (1988). J. Med. Chem. 31: 2235 http://dx.doi.org/10.1021/jm00120a002. Недостаје или је празан параметар |title= (помоћ)

[1]

[2]

[3]

[4]

[5]

[6]

[7]